Accession Number:

AD1001602

Title:

Targeted Iron Chelation Will Improve Recovery after Spinal Cord Injury

Descriptive Note:

Technical Report,30 Sep 2010,29 Sep 2014

Corporate Author:

Ohio State University Research Foundation Columbus United States

Personal Author(s):

Report Date:

2014-10-01

Pagination or Media Count:

30.0

Abstract:

Following spinal cord injury there is a protracted accumulation of iron at the site of the injury. Iron plays a role in multiple damaging pathways following injury but is also essential for maximal oligodendrogenesis. The current experiments investigate the therapeutic potential of iron chelation following traumatic spinal cord injury. Our initial research indicates that if iron chelation with the Federal Drug Administration FDA approved drug Exjade is begun approximately 1.5 hours after a spinal cord injury there is limited improvement in locomotor function and increased spared of grey matter. Since iron accumulation occurs in a protracted manner, we also investigated the potential of delayed the start of Exjade treatment by 1 week. This paradigm, however, did not result in any of the improvements observed in the early onset treatment. Increasing the dose of Exjade to 320mgkgday resulted in increased mortality and therefore was discontinued. In attempts to improve the effects of iron chelation, we have conducted experiments using a different FDA approved chelator, deferiprone. Following either contusive or hemisection spinal cord injury, deferiprone improves functional and histological outcome.

Descriptors:

Subject Categories:

Distribution Statement:

APPROVED FOR PUBLIC RELEASE